Last Updated on January 19, 2024 by The Health Master
Eton Pharma said yesterday the US Food and Drug Administration (USFDA) declined to approve its anti-seizure drug lamotrigine, sending the drugmaker’s shares down 13 per cent in extended trading.
Eton was notified that its privately held partner Azurity Pharma received a complete response letter from the health regulator for lamotrigine, it said in a regulatory filing.
Lamotrigine was one of the three drugs in Eton’s neurology portfolio that the drugmaker sold to Azurity Pharma last year for up to $45 million in milestone payments.
The drug is a liquid form of a widely available anti-convulsant or anti-epileptic oral tablet, which also goes by the name lamotrigine.
It helps stabilise electrical activity inside the brain and makes it harder for certain neurons to get stimulated, thus preventing seizures.
The drugmaker did not disclose the details of the complete response letter and added that it was assessing the USFDA’s comments along with its partner.
Eton and Azurity did not immediately respond to Reuters’ requests for more details on the complete response letter.
In 2020, the USFDA declined to approve the use of the drug, citing the need for an additional study to show that patients can prepare and administer the oral suspension safely and effectively.
The drugmaker’s partner submitted results from the additional study to the USFDA in the fourth quarter of 2021.
USFDA declines to authorise this viral skin disease treatment
USFDA declines pediatric EUA for vaccine Covaxin
USFDA declines to approve Gilead’s HIV drug on this concern
USFDA declines to approve GSK’s HIV inj.
AIOCD seeks 10% trade margin for wholesalers & 20% for retailers
Govt to relax conditions on liquid antiseptics under Schedule K
Govt: Draft notification to add 16 drugs as OTC under Schedule K of Drugs Rules
USFDA declines to authorise this viral skin disease treatment
Govt to amend Drugs Rules 1945 for parallel submission of marketing and manufacturing approvals
After blood transfusion, 4 children become HIV positive, FDA starts investigation
USFDA lifts hold on Covaxin’s clinical trials
Govt allows import of Oxytocin Reference Standards for test & analysis
USFDA issues final approval to Alembic for Pirfenidone tablets
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
